

Date: 14<sup>th</sup> February, 2024  
The Manager  
BSE Ltd.  
25<sup>th</sup> Floor, Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai - 400 001  
Script Code: 540359

**Sub.: Outcome of the meeting of the Board of Directors of the Company**

Dear Sirs,

In continuation of our Corporate announcement dated 7<sup>th</sup> February, 2024 we hereby inform you that the Board of Directors of the Company has, at its meeting held today, inter—alia, considered and approved the Unaudited Financial Results for quarter and nine months ended 31<sup>st</sup> December, 2023. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and Nine months ended 31<sup>st</sup> December, 2023 is enclosed.

Further we are submitting the Limited Review report on Unaudited Financial Results for quarter and Nine months ended 31<sup>st</sup> December, 2023 issued by our Statutory Auditors i.e. M/s. B A Shah S R Mehta & Co.

The meeting was commenced at 04.30 pm and was concluded at 7.15 pm.

Kindly take this on your records.

Thanking you,

Yours faithfully,  
For Parmax Pharma Limited



Umang Gosalia  
Managing Director

Encl: As above

**PARMAX PHARMA LIMITED**

**Regd. Off. & Factory** : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 - 36 **e-mail** : info@parmaxpharma.com **CIN** : L24231GJ1994PLC023504

**Correspondence Add.:** A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

Statement of Standalone Unaudited Results for the Quarter & Nine Months ended 31.12.2023							(in Rs. Thousands)
Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	13273.27	40680.96	53532.39	67955.65	90424.12	182511.20
II.	Other income	109.48	93.34	86.85	339.78	248.06	627.81
III.	<b>Total Income (I+II)</b>	<b>13382.75</b>	<b>40774.30</b>	<b>53619.24</b>	<b>68295.43</b>	<b>90672.18</b>	<b>183139.00</b>
IV.	<b>Expenses</b>						
	(a) Cost of materials consumed	5989.52	13824.44	46908.44	22641.85	64634.05	67179.40
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	254.32	13525.27	-41093.29	15240.35	-45683.80	-61.00
	(d) Employee benefits expense	8379.65	8489.54	11403.82	24119.11	22006.20	34616.07
	(e) Finance Costs	1561.61	1812.56	1062.89	4591.30	3147.93	3858.12
	(f) Depreciation and amortisation expense	4537.31	4322.62	4776.35	13047.75	14056.96	19320.89
	(g) Other expenses*	10188.16	12484.09	13124.62	31656.04	35281.12	55192.82
	<b>Total expenses (IV)</b>	<b>30910.55</b>	<b>54458.52</b>	<b>36182.83</b>	<b>111296.40</b>	<b>93442.47</b>	<b>180106.31</b>
V.	<b>Profit/(Loss) from operations before exceptional items and tax (I-IV)</b>	<b>-17527.80</b>	<b>-13684.23</b>	<b>17436.41</b>	<b>-43000.97</b>	<b>-2770.29</b>	<b>3032.70</b>
VI.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0
VII.	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>-17527.80</b>	<b>-13684.23</b>	<b>17436.41</b>	<b>-43000.97</b>	<b>-2770.29</b>	<b>3032.70</b>
VIII.	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	2250.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	632.43
IX.	<b>Net Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-17527.80</b>	<b>-13684.23</b>	<b>17436.41</b>	<b>-43000.97</b>	<b>-2770.29</b>	<b>1415.13</b>
X.	Profit/(loss) from discontinued operations				0.00	0.00	
XI.	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0
XII.	<b>Profit/(loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0</b>
XIII.	<b>Profit (Loss) for the period (IX+XII)</b>	<b>-17527.80</b>	<b>-13684.23</b>	<b>17436.41</b>	<b>-43000.97</b>	<b>-2770.29</b>	<b>1415.13</b>
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	<b>Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)</b>	<b>-17527.80</b>	<b>-13684.23</b>	<b>17436.41</b>	<b>-43000.97</b>	<b>-2770.29</b>	<b>1415.13</b>
XVI.	Paid-up equity share capital (Face Value Rs 10)	37413.00	37413.00	37413.00	37413.00	37413.00	37413.00
XVII.	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	-4.68	-3.66	4.66	-11.49	-0.74	0.38
	(b) Diluted	0.00	0.00	0.00	0.00	0.00	0.00

## PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1904PLG033504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

**Notes:**

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14.02.2024
  2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and nine months ended 31st December, 2023
  3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
  4. Statement of Unaudited Financial Results of the company for the quarter and nine months ended 31st December, 2023, in the prescribed format under Schedule III of Companies Act, 2013
  5. The figures for the previous period have been regrouped wherever necessary.
  6. During the quarter under review, on 6th December 2023, a fire broke out at manufacturing facility of the company situated at Plot no. 20, Survey no. 52, Rajkot- Gondal national highway no.27, Hadamtala, Rajkot-360311, Gujarat resulted in loss / damage of Fixed assets, plant machineries, electrification of the Company. Process of assessing the actual damage due to fire is still under evaluation hence no effect of any loss due to fire is accounted in the financials of quarter and nine months ended 31.12.2023.
- \* The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

Place Hadamtala (Rajkot)  
Date: 14.02.2024

FOR, PARMAX PHARMA LIMITED

*U. Gosalia*

Dr. Umang Gosalia  
Managing Director



**PARMAX PHARMA LIMITED**

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. Tel.: Fac.+91-2827-270534 - 35 - 36 e-mail : info@parmaxpharma.com CIN : L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

# B A SHAH S R MEHTA & Co.

## Chartered Accountants

Partner

**Malay B Shah**

B.Com. F.C.A.

M. No. 159526

Partner

**Zarna M Shah**

M.Com. F.C.A. DISA

(Information Systems Audit)

M. No. 144246

### Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,  
**PARMAX PHARMA LIMITED**

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and Nine months ended **31st December 2023** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14<sup>th</sup> February 2024**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

*Based on our review conducted as above, nothing has come to our attention except actual damage/loss due to fire broke out on 06.12.2023 at factory premises which is not ascertained as it is under process and not provided in the Books of Accounts that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there*

Head Office:  
209-Sapphire Complex, II<sup>nd</sup> Floor  
21/25-B New Jagnath Plot,  
Dr.Yagnik Road  
**RAJKOT- 360 001**  
(GUJARAT)



Electronic Address:  
(T) 0281-2468261  
  
(M) 09427564149  
(E) bassrmco.office@gmail.com  
Or  
mbshah\_31@hotmail.com

# B A SHAH S R MEHTA & Co.

## Chartered Accountants

Partner  
**Malay B Shah**  
B.Com. F.C.A.  
M. No. 159526

Partner  
**Zarna M Shah**  
M.Com. F.C.A. DISA  
(Information Systems Audit)  
M. No. 144246

under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatement.

Place : Rajkot

Date : 14.02.2024



For **B. A. SHAH S R MEHTA & Co.**  
Chartered Accountants  
FRN NO : 128796W

A handwritten signature in blue ink that reads "Malay B Shah".

**MALAY B SHAH**

Partner

M. No. 159526

**UDIN : 24159526BKFOSA1443**

Head Office:  
209-Sapphire Complex, II<sup>nd</sup> Floor  
21/25-B New Jagnath Plot,  
Dr.Yagnik Road  
RAJKOT- 360 001  
(GUJARAT)

Electronic Address:  
(O) 0281-2468261

(M) 09427564149  
(E) bassrmco.office@gmail.com

Or  
mbshah\_31@hotmail.com